Response of a nonmalignant pleural effusion to bevacizumab [7]

New England Journal of Medicine

Volumn 353, Issue 7, 2005, Pages 740-741

  Pichelmayer, Oskar ^a   Zielinski, Christoph ^a   Raderer, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; C REACTIVE PROTEIN; DIURETIC AGENT; VASCULOTROPIN ANTIBODY; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

AGED; CANCER CELL; CASE REPORT; CYTOLOGY; DYSPNEA; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; LETTER; MALE; MICTURITION; PLEURA EFFUSION; PLEURA FLUID; PRIORITY JOURNAL; THORACOCENTESIS; THORAX RADIOGRAPHY; TREATMENT OUTCOME; AMYLOIDOSIS; HEART DISEASE; IMMUNOLOGY; RADIOGRAPHY;

AGED; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; DYSPNEA; HEART DISEASES; HUMANS; MALE; PLEURAL EFFUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23844537198     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM200508183530722     Document Type: Letter

References (4)

1. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
2. Sack U, Hoffmann M, Zhao XJ, et al. Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 2005;25:600-4.
3. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.